Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
22 hedge funds and large institutions have $11.2M invested in Acura Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
229% more call options, than puts
Call options by funds: $46K | Put options by funds: $14K
10% more capital invested
Capital invested by funds: $10.2M → $11.2M (+$985K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$11.3K |
| 2 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
+$2.15K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$765 |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$655 |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$213 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$168K |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$68K |
| 3 |
SIM
Spark Investment Management
New York
|
-$39K |
| 4 |
Walleye Trading
New York
|
-$3.44K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$487 |
ACUR Hedge Fund Activity: Q1 2016 in Review
22 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q1 2016, worth a combined $11.2M — up 9.7% from $10.2M a quarter earlier.
Fund positioning in ACUR was balanced in Q1 2016: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $11.3K. The largest seller was Sabby Management, cutting an estimated $168K.
- 22 institutional investors held Acura Pharmaceuticals (ACUR) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $11.2M of Acura Pharmaceuticals stock for Q1 2016, up 9.7% quarter-over-quarter.
- 3 funds opened new Acura Pharmaceuticals positions in Q1 2016 and 3 closed out, a net change of 0 holders.
- The largest Acura Pharmaceuticals buyer in Q1 2016 was Renaissance Technologies, an estimated $11.3K added.
- The largest Acura Pharmaceuticals seller in Q1 2016 was Sabby Management, an estimated $168K sold.
Based on aggregated 13F filings for Q1 2016.